The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments
Open accessAbstract
siRNA is a promising therapeutic solution to address gene overexpression or mutations as a post-transcriptional gene regulation process for several pathological conditions such as viral infections, cancer, genetic disorders, and autoimmune disorders like arthritis. This therapeutic method is currently being actively pursued in cancer therapy because siRNA has been found to suppress the oncogenes and address mutations in tumor suppressor genes and elucidate the key molecules in cellular pathways in cancer. It is also effective in personalized gene therapy for several diseases due to its specificity, adaptability, and broad targeting capability. However, naked siRNA is unstable in the bloodstream and cannot efficiently cross cell membranes besides being immunogenic. Therefore, careful design of the delivery systems is essential to fully utilize the potential of this therapeutic solution. This review presents a comprehensive update on the challenges of siRNA delivery and the current strategies used to develop nanoparticulate delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
(1989) · PubMed · Cited by 3,343
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 3×
“Yet another method is using neutrally charged ionizable lipids that become positively charged inside an endosome that leads to their disruption to release the siRNA carriers [37].”
BackgroundMethodInterfering with pH regulation in tumours as a therapeutic strategy
Neri, D., & Supuran, C. T. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3554 · Cited by 1,547
Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi
Martinez, J., Patkaniowska, A., Urlaub, H., Lührmann, R., & Tuschl, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00908-x · Cited by 1,459
Lysosomal acidification mechanisms
Mindell, J. A. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142317 · Cited by 1,258
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
Killing the messenger: short RNAs that silence gene expression
Dykxhoorn, D. M., Novina, C. D., & Sharp, P. A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1129 · Cited by 1,182
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Mechanism of DNA Release from Cationic Liposome/DNA Complexes Used in Cell Transfection,
Xu, Y., & Szoka, F. C. (1996) · Biochemistry · doi:10.1021/bi9602019 · Cited by 1,134
Chloride Accumulation and Swelling in Endosomes Enhances DNA Transfer by Polyamine-DNA Polyplexes
Sonawane, N. D., Szoka, F. C., & Verkman, A. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308643200 · Cited by 1,081
Kobayashi, H., Watanabe, R., & Choyke, P. L. (2014) · Theranostics · doi:10.7150/thno.7193 · Cited by 996
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 956
Huang, K., Ma, H., Liu, J., Huo, S., Kumar, A., Wei, T., Zhang, X., Jin, S., Gan, Y., Wang, P. C., et al. (2012) · ACS Nano · doi:10.1021/nn301282m · Cited by 840
The lysosome: from waste bag to potential therapeutic target
Appelqvist, H., Wäster, P., Kågedal, K., & Öllinger, K. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt022 · Cited by 772 · cited 1×
“Ideally, the endosomal escape should happen before the late endosomes fuse with the lysosomes which contain digestive enzymes, a process which involves a gradual drop in the pH inside the endosome from the early endosomal stage to the lysosomal fusion stage [34,35].”
BackgroundCurrent prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658
Hatakeyama, H., Akita, H., & Harashima, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.001 · Cited by 645
Muthu, M. S., Leong, D. T., Mei, L., & Feng, S.-S. (2014) · Theranostics · doi:10.7150/thno.8698 · Cited by 603
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma
Jensen, S. A., Day, E. S., Ko, C. H., Hurley, L. A., Luciano, J. P., Kouri, F. M., Merkel, T. J., Luthi, A. J., Patel, P. C., Cutler, J. I., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006839 · Cited by 592
Self-Cross-Linked Polymer Nanogels: A Versatile Nanoscopic Drug Delivery Platform
Ryu, J.-H., Chacko, R. T., Jiwpanich, S., Bickerton, S., Babu, R. P., & Thayumanavan, S. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1069932 · Cited by 553
Deng, Z. J., Morton, S. W., Ben-Akiva, E., Dreaden, E. C., Shopsowitz, K. E., & Hammond, P. T. (2013) · ACS Nano · doi:10.1021/nn4047925 · Cited by 516
Magnetic nanoparticle drug delivery systems for targeting tumor
Mody, V. V., Cox, A., Shah, S., Singh, A., Bevins, W., & Parihar, H. (2014) · Applied Nanoscience · doi:10.1007/s13204-013-0216-y · Cited by 497
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery
Li, J., Chen, Y.-C., Tseng, Y.-C., Mozumdar, S., & Huang, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.008 · Cited by 470
Aptamer mediated siRNA delivery
Chu, T. C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl388 · Cited by 446
Glutathione metabolism and Parkinson's disease
Smeyne, M., & Smeyne, R. J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.001 · Cited by 435
Layer-by-Layer Assembled Gold Nanoparticles for siRNA Delivery
Elbakry, A., Zaky, A., Liebl, R., Rachel, R., Goepferich, A., & Breunig, M. (2009) · Nano Letters · doi:10.1021/nl9003865 · Cited by 425
Recent progress in development of siRNA delivery vehicles for cancer therapy
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.011 · Cited by 424
Sun, T.-M., Du, J.-Z., Yao, Y.-D., Mao, C.-Q., Dou, S., Huang, S.-Y., Zhang, P.-Z., Leong, K. W., Song, E.-W., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Prospects of RNA interference therapy for cancer
Pai, S. I., Lin, Y.-Y., Macaes, B., Meneshian, A., Hung, C.-F., & Wu, T.-C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302694 · Cited by 352
Glutathione and modulation of cell apoptosis
Circu, M. L., & Aw, T. Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.06.019 · Cited by 331
Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography
Wartiovaara, J., Öfverstedt, L.-G., Khoshnoodi, J., Zhang, J., Mäkelä, E., Sandin, S., Ruotsalainen, V., Cheng, R. H., Jalanko, H., Skoglund, U., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22562 · Cited by 319
Li, J., Yang, Y., & Huang, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.020 · Cited by 306
Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides
Meade, B. R., & Dowdy, S. F. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.004 · Cited by 274
A computational study of off-target effects of RNA interference
Qiu, S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki324 · Cited by 274
RNAi Therapies: Drugging the Undruggable
Wu, S. Y., Lopez-Berestein, G., Calin, G. A., & Sood, A. K. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008362 · Cited by 273
Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.039 · Cited by 256
Ashley, C. E., Carnes, E. C., Epler, K. E., Padilla, D. P., Phillips, G. K., Castillo, R. E., Wilkinson, D. C., Wilkinson, B. S., Burgard, C. A., Kalinich, R. M., et al. (2012) · ACS Nano · doi:10.1021/nn204102q · Cited by 239
Hom, C., Lu, J., Liong, M., Luo, H., Li, Z., Zink, J. I., & Tamanoi, F. (2010) · Small · doi:10.1002/smll.200901966 · Cited by 239
Yu, H., Zou, Y., Wang, Y., Huang, X., Huang, G., Sumer, B. D., Boothman, D. A., & Gao, J. (2011) · ACS Nano · doi:10.1021/nn203503h · Cited by 238
Nanodiamond as a Vector for siRNA Delivery to Ewing Sarcoma Cells
Alhaddad, A., Adam, M., Botsoa, J., Dantelle, G., Perruchas, S., Gacoin, T., Mansuy, C., Lavielle, S., Malvy, C., Treussart, F., et al. (2011) · Small · doi:10.1002/smll.201101193 · Cited by 231
Theranostic nanoparticles for future personalized medicine
Ryu, J. H., Lee, S., Son, S., Kim, S. H., Leary, J. F., Choi, K., & Kwon, I. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.027 · Cited by 222
Current issues of RNAi therapeutics delivery and development
Haussecker, D. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.056 · Cited by 217
Li, J., Yu, X., Wang, Y., Yuan, Y., Xiao, H., Cheng, D., & Shuai, X. (2014) · Advanced Materials · doi:10.1002/adma.201403877 · Cited by 215
A review of the current status of siRNA nanomedicines in the treatment of cancer
Resnier, P., Montier, T., Mathieu, V., Benoit, J.-P., & Passirani, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.060 · Cited by 210
Matrix metalloproteinases: protective roles in cancer
Decock, J., Thirkettle, S., Wagstaff, L., & Edwards, D. R. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01302.x · Cited by 205
Cruz, L. J., Tacken, P. J., Fokkink, R., & Figdor, C. G. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.082 · Cited by 201
Applications of inorganic nanoparticles as therapeutic agents
Kim, T., & Hyeon, T. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/1/012001 · Cited by 180
Update on the glomerular filtration barrier
Jarad, G., & Miner, J. H. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283296044 · Cited by 179
Endres, T. K., Beck-Broichsitter, M., Samsonova, O., Renette, T., & Kissel, T. H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.064 · Cited by 175
Pittella, F., Zhang, M., Lee, Y., Kim, H. J., Tockary, T., Osada, K., Ishii, T., Miyata, K., Nishiyama, N., & Kataoka, K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.057 · Cited by 169
Stable RNA interference rules for silencing
Fellmann, C., & Lowe, S. W. (2014) · Nature Cell Biology · doi:10.1038/ncb2895 · Cited by 163
Nanoparticle-siRNA: A potential cancer therapy?
Young, S. W. S., Stenzel, M., & Jia-Lin, Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.015 · Cited by 161
Delivery strategies and potential targets for siRNA in major cancer types
Lee, S. J., Kim, M. J., Kwon, I. C., & Roberts, T. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.010 · Cited by 153
Elimination Pathways of Systemically Delivered siRNA
Huang, Y., Hong, J., Zheng, S., Ding, Y., Guo, S., Zhang, H., Zhang, X., Du, Q., & Liang, Z. (2010) · Molecular Therapy · doi:10.1038/mt.2010.266 · Cited by 152
Kim, H. J., Takemoto, H., Yi, Y., Zheng, M., Maeda, Y., Chaya, H., Hayashi, K., Mi, P., Pittella, F., Christie, R. J., et al. (2014) · ACS Nano · doi:10.1021/nn502125h · Cited by 143
Zhang, L., Li, Y., & Yu, J. C. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb21196g · Cited by 140
Dogini, D. B., Pascoal, V., Avansini, S. H., Vieira, A. S., Pereira, T. C., & Lopes‐Cendes, Í. (2014) · Genetics and Molecular Biology · doi:10.1590/s1415-47572014000200014 · Cited by 131
Matrix metalloproteinase 2-responsive micelle for siRNA delivery
Wang, H., Yang, X., Sun, C., Mao, C., Zhu, Y., & Wang, J. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.050 · Cited by 130
Imaging-guided delivery of RNAi for anticancer treatment
Wang, J., Mi, P., Lin, G., Wáng, Y. X. J., Liu, G., & Chen, X. S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.008 · Cited by 127
Matrix Metalloproteinase Responsive, Proximity‐Activated Polymeric Nanoparticles for siRNA Delivery
Li, H., Yu, S. S., Miteva, M., Nelson, C. E., Werfel, T. A., Giorgio, T. D., & Duvall, C. L. (2013) · Advanced Functional Materials · doi:10.1002/adfm.201202215 · Cited by 122
Suma, T., Miyata, K., Anraku, Y., Watanabe, S. T., Christie, R. J., Takemoto, H., Shioyama, M., Gouda, N. A., Ishii, T., Nishiyama, N., et al. (2012) · ACS Nano · doi:10.1021/nn301164a · Cited by 108
Kakizawa, Y., Furukawa, S., Ishii, A., & Kataoka, K. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.004 · Cited by 107
Gene transfer into guinea pig cochlea using adeno‐associated virus vectors
Konishi, M., Kawamoto, K., Izumikawa, M., Kuriyama, H., & Yamashita, T. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1189 · Cited by 103
Hama, S., Itakura, S., Nakai, M., Nakayama, K., Morimoto, S., Suzuki, S., & Kogure, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.011 · Cited by 101
Structural insights into RNA interference
Sashital, D. G., & Doudna, J. A. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.12.001 · Cited by 90
Nanoparticle delivery systems for siRNA-based therapeutics
Li, J., Xue, S., & Mao, Z. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01462c · Cited by 72
Zhao, M., Sun, J., & Zhao, Z. (2013) · Molecular BioSystems · doi:10.1039/c3mb70172g · Cited by 42
Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery
Li, L., Wang, R., Wilcox, D. M., Zhao, X. B., Song, J. C., Li, X., Kohlbrenner, W. M., Fesik, S. W., & Shen, Y. (2011) · Gene Therapy · doi:10.1038/gt.2011.146 · Cited by 34
Guo, J., Rahme, K., Fitzgerald, K. A., Holmes, J. D., & O’Driscoll, C. M. (2015) · Nano Research · doi:10.1007/s12274-015-0829-4 · Cited by 21
Li, W., Hu, Z.-F., Chen, B., & Ni, G. (2013) · BioMed Research International · doi:10.1155/2013/326346 · Cited by 19
Cited by
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507
Loh, C.-Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00048 · Cited by 348
RNA interference-based therapy and its delivery systems
Chen, X., Mangala, L. S., Rodriguez-Aguayo, C., Kong, X., Lopez-Berestein, G., & Sood, A. K. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9717-6 · Cited by 329
Milk exosomes - Natural nanoparticles for siRNA delivery
Aqil, F., Munagala, R., Jeyabalan, J., Agrawal, A. K., Kyakulaga, A.-H., Wilcher, S. A., & Gupta, R. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.011 · Cited by 314
Metadata
- Authors
- Tatiparti, K., Sau, S., Kashaw, S., & Iyer, A.
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2017-04-05
- Volume
- 7
- Issue
- 4
- Pages
- 77
- ISSN
- 2079-4991 (ISSN-L)
- OpenAlex
- W2605100193
- Cited by
- 429
- References
- 79
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.